Company
Evercrisp Biosciences
Innovating at the molecular level to enable precise, safe, and scalable delivery of genetic therapies into target tissues
Also known as EVERCRISP BIOSCIENCES, INC.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- EVERCRISP BIOSCIENCES, INC.
Claim, correct or request removal
Record updated 28 September 2026
About
Evercrisp’s platform is built on machine learning-engineered miniproteins for receptor-mediated delivery of protein and oligonucleotide payloads directly into specific cells, to reach previously inaccessible tissues.
Funding snapshot
- Total raised
- $3.5MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $3.5M2021-08-11
Funding rounds
- Round, 2021
- $3.5M2021-08-11, SEC form D sold, 1 investor
Loading relationship preview